» Articles » PMID: 24885430

Predictors of Pathological Complete Response to Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma

Overview
Publisher Biomed Central
Date 2014 Jun 3
PMID 24885430
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Backgrounds: In this study, we evaluated the factors associated with a pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) for esophageal squamous cell carcinoma (ESCC).

Methods: Pre-nCRT parameters in ESCC patients treated between 1999 and 2006 were analyzed to identify predictors of pCR. All patients received 5-fluorouracil/cisplatin-based chemotherapy and external beam radiation followed by scheduled esophagectomy. Variables were analyzed using univariate and multivariate analyses with pCR as the dependent variable. Estimated pCR rate was calculated with a regression model.

Results: Fifty-nine (20.9%) of 282 patients achieved pCR. Univariate analysis identified four patient factors (age, smoking status, drinking history and hypertension), one pre-nCRT parameter (tumor length) as significant predictors of pCR (all P <0.05). On multivariate analysis, tumor length ≤3 cm (favorable, odds ratio (OR): 4.85, P = 0.001), patient age >55 years (favorable, OR: 1.95, P = 0.035), and being a non-smoker (favorable, OR: 3.6, P = 0.003) were independent predictors of pCR. The estimated pCR rates based on a logistic regression including those three predictors were 71%, 35 to approximately 58%, 19 to approximately 38%, and 12% for patients with 3, 2, 1 and 0 predictors, respectively.

Conclusion: Age, smoking habit and tumor length were important pCR predictors. These factors may be used to predict outcomes for ESCC patients receiving nCRT, to develop risk-adapted treatment strategies, and to select patients who could participate in trials on new therapies.

Citing Articles

CT-based delta-radiomics nomogram to predict pathological complete response after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma patients.

Fan L, Yang Z, Chang M, Chen Z, Wen Q J Transl Med. 2024; 22(1):579.

PMID: 38890720 PMC: 11186275. DOI: 10.1186/s12967-024-05392-4.


An updated review of immunotherapy in esophageal cancer: PD-L1 footprint.

Yao J, Tan X, Sha Y, Chen Y, Chen R, Shi D Cent Eur J Immunol. 2024; 49(1):77-90.

PMID: 38812606 PMC: 11130989. DOI: 10.5114/ceji.2024.139269.


Neoadjuvant Chemoradiation Followed by Surgery for Locally Advanced Squamous Cell Carcinoma Esophagus: Demographics and Evaluation of Prognostic Factors at a Tertiary Care Center in India.

Mithi M, Sharma M, Puj K, Hazarika P, Pandya S, Gandhi J Indian J Surg Oncol. 2024; 15(1):129-135.

PMID: 38511020 PMC: 10948642. DOI: 10.1007/s13193-023-01828-3.


Endoscopic findings suggestive of a high risk of non-radical cure after definitive chemoradiotherapy for cT1bN0M0 esophageal squamous cell carcinoma.

Fukuhara M, Urabe Y, Oka S, Ishibashi K, Konishi H, Mizuno J Esophagus. 2023; 20(3):541-547.

PMID: 37027046 DOI: 10.1007/s10388-023-00999-w.


Multi-omics to predict acute radiation esophagitis in patients with lung cancer treated with intensity-modulated radiation therapy.

Zheng X, Guo W, Wang Y, Zhang J, Zhang Y, Cheng C Eur J Med Res. 2023; 28(1):126.

PMID: 36935504 PMC: 10024847. DOI: 10.1186/s40001-023-01041-6.


References
1.
Warnecke-Eberz U, Metzger R, Miyazono F, Baldus S, Neiss S, Brabender J . High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res. 2004; 10(11):3794-9. DOI: 10.1158/1078-0432.CCR-03-0079. View

2.
Oze I, Matsuo K, Ito H, Wakai K, Nagata C, Mizoue T . Cigarette smoking and esophageal cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2011; 42(1):63-73. DOI: 10.1093/jjco/hyr170. View

3.
Rohatgi P, Swisher S, Correa A, Wu T, Liao Z, Komaki R . Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005; 104(11):2365-72. DOI: 10.1002/cncr.21439. View

4.
Sundelof M, Lagergren J, Ye W . Patient demographics and lifestyle factors influencing long-term survival of oesophageal cancer and gastric cardia cancer in a nationwide study in Sweden. Eur J Cancer. 2008; 44(11):1566-71. DOI: 10.1016/j.ejca.2008.04.002. View

5.
Shitara K, Matsuo K, Hatooka S, Ura T, Takahari D, Yokota T . Heavy smoking history interacts with chemoradiotherapy for esophageal cancer prognosis: a retrospective study. Cancer Sci. 2010; 101(4):1001-6. PMC: 11159654. DOI: 10.1111/j.1349-7006.2009.01466.x. View